title: Targeted IgE Therapy for Patients With Moderate to Severe Asthma.
abstract: It is well established that the proinflammatory cytokine immunoglobulin E (IgE) is a primary contributor to development of allergic airway inflammation following allergen exposure. Recent data suggest that blocking the effects of IgE with omalizumab, a recombinant DNA-derived humanized monoclonal antibody that inhibits the binding of IgE, is an effective strategy for the treatment of asthma, particularly for moderate to severe asthma that is difficult to control with inhaled corticosteroids and traditional controller medications. Targeting specific steps in the inflammatory cascade with omalizumab improves daytime and nocturnal symptom control, reduces exacerbations, and decreases the need for inhaled corticosteroids and beta(2) agonists. These benefits, along with improved daily functioning, have resulted in a clinically meaningful improvement in asthma-related quality of life for a substantial number of patients. This paper briefly reviews the contribution of IgE to the development of airway inflammation, discusses the clinical benefits of IgE-blocker therapy, and profiles the patient who stands to benefit from this new and innovative form of therapy.
authors: Medical Director, Capital Allergy and Respiratory Disease Center, Sacramento, Calif.
authors: Bradley E
authors: BE
authors: Chipps
authors: Patricia L
authors: PL
authors: Marshik
references: J Immunol. 1997 Feb 1;158(3):1438-45
references: 9013989
references: Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):787-93
references: 9309994
references: N Engl J Med. 1991 Oct 10;325(15):1067-71
references: 1891008
references: N Engl J Med. 1989 Feb 2;320(5):271-7
references: 2911321
references: Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 2):S12-7
references: 11704612
references: J Allergy Clin Immunol. 2001 Aug;108(2):184-90
references: 11496232
references: Curr Med Res Opin. 2001;17(4):233-40
references: 11922396
references: Am J Respir Crit Care Med. 1996 Apr;153(4 Pt 1):1273-9
references: 8616553
references: Eur Respir J. 2002 Nov;20(5):1088-94
references: 12449159
references: Am J Respir Crit Care Med. 1997 Jun;155(6):1835-40
references: 9196083
references: Am Rev Respir Dis. 1993 Apr;147(4):832-8
references: 8466117
references: J Allergy Clin Immunol. 2003 Jan;111(1):87-90
references: 12532101
references: Clin Exp Allergy. 2000 Jun;30 Suppl 1:16-21
references: 10849469
references: J Biol Chem. 1994 Oct 21;269(42):26368-73
references: 7929356
references: JAMA. 1997 Dec 10;278(22):1855-73
references: 9396647
references: J Allergy Clin Immunol. 2002 Nov;110(5 Suppl):S141-219
references: 12542074
references: Eur Respir J. 2001 Aug;18(2):254-61
references: 11529281
references: J Clin Invest. 1997 Mar 1;99(5):879-87
references: 9062345
references: Am J Respir Crit Care Med. 1997 Jun;155(6):1828-34
references: 9196082